Alerta

Adipose-derived stem cell exosome and application thereof in treating colitis and mesentery

Resumen de: CN119454756A

The invention provides an adipose-derived stem cell exosome and application of the adipose-derived stem cell exosome in treatment of colitis and mesentery. It is verified for the first time that the adipose-derived stem cell exosome CrF-exo from crawling adipose tissue regulates the lymphatic endothelial cell function and promotes lymphatic drainage in colon and mesentery and finally relieves inflammation of the colon and mesentery, and it is found through verification that CrF-exo-miR-132-3p promotes the lymphatic endothelial cell function and CCL21 secretion through an RASA1/ERK1/2 axis; the miR-132-3p is highly expressed in CrF and inflammatory intestines of a CD patient along with increase of lymphatic vessel density; the expression of miR-132-3p in serum of a patient is also increased and is negatively correlated with an inflammation biomarker. The research result provides a new insight for the effect of the mesenteric lymphatic function in CD progress and a potential treatment method for targeting lymphatic vessels to treat CD mesenteric and intestinal lesions.

CCDC71L在诊断及治疗放射性肠炎中的应用

Resumen de: CN119433017A

本发明公开了CCDC71L在诊断及治疗放射性肠炎中的应用，本发明提供了检测CCDC71L表达水平的试剂在制备放射性肠炎诊断的产品中的应用及CCDC71L的抑制剂在制备治疗放射性肠炎的药物中的应用，还提供了一种筛选治疗或预防放射性肠炎的候选药物的方法及一种抑制巨噬细胞中炎症因子表达水平的方法。本发明通过实验证明，CCDC71L能够实现放射性肠炎的诊断，并且发现抑制CCDC71L能够抑制巨噬细胞的浸润和极化进而抑制辐射诱导的炎症反应，本发明提供的CCDC71L标志物为放射性肠炎的诊断与治疗提供了新的思路，具有广阔的应用前景。

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

Resumen de: JP2025023316A

To provide variants of TNFSF15 and DCR3 associated with Crohn's disease.SOLUTION: Described herein are a method and a composition related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides a method of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.SELECTED DRAWING: Figure 4

蛋白标志物在制备检测炎症性肠病的检测产品中的应用

Resumen de: CN119438591A

本申请提供了一种蛋白标志物在制备检测炎症性肠病的检测产品中的应用。其中，蛋白标志物选自如下任意一个或多个蛋白分子：MRPL43、ECHS1、TLN2、ENO3、NCSTN、CTSH、CKMT1、TUBA4A、DYNC1H1、PDLIM3、GLB1及PMPCA。本申请通过实验证明了上述12个蛋白的瓜氨酸水平与炎症性肠病高度关联，因而可将其中的一个或多个作为蛋白标志物来制备检测炎症性肠病的检测产品(比如检测或诊断试剂盒等)。基于上述蛋白标志物的检测产品有助于实现尽早检测和无创检测，快捷、方便、准确。

一种用于炎症性肠病诊断的粪便生物标志物及其应用

Resumen de: CN119395122A

本发明公开了一种用于炎症性肠病诊断的粪便生物标志物及其应用，该粪便生物标志物为肾上腺酸。本发明通过实验首次发现了肾上腺酸在IBD患者粪便样本中呈现上调，经检测发现肾上腺酸在IBD患者粪便标本中表达上调；进一步通过ROC曲线分析肾上腺酸相比于其他钙粘蛋白等炎症活动指标而言，具有较好的诊断敏感度和特异性。本发明为IBD的临床诊断提供了新的诊断标志物，以肾上腺酸作为IBD诊断的粪便生物标志物，用于炎症性肠病的诊断，具有检测精确度高、特异性和灵敏性高、方便快捷以及安全无创等优点，对判断IBD的活动状态、调整IBD患者的诊疗及管理等均具有重要意义。

抗TL1A抗体及其制备方法和应用

Resumen de: CN119390843A

本申请公开了生物医药技术领域的一种抗TL1A抗体及其制备方法和应用。其包括重链可变区和轻链可变区，其中，所述重链可变区包含氨基酸序列如SEQ ID NO:7~9所示的HCDR1、HCDR2和HCDR3；所述轻链可变区包含氨基酸序列如SEQ ID NO:10~12所示的LCDR1、LCDR2和LCDR3。该抗TL1A抗体的生物活性表征更优，且表位与传统抗TL1A抗体不同。

In-vitro bionic intestinal barrier injury micro-physiological system

Nº publicación: CN119391523A 07/02/2025

Solicitante:

UNIV JIANGNAN
\u6C5F\u5357\u5927\u5B66

Resumen de: CN119391523A

The invention discloses an in-vitro bionic intestinal barrier injury micro-physiological system. The device comprises a stomach digestion simulation system, a small intestine digestion simulation system, a small intestine interaction simulation system, a large intestine glycolysis simulation system and a large intestine interaction simulation system. According to the invention, the physicochemical environment for digestion of patients with inflammatory bowel diseases (IBD) is simulated by adjusting parameters such as pH, and the physiological system of the patients with IBD is simulated through human-derived organs and microorganisms. The in-vitro substitution model not only simulates gastrointestinal digestion, absorption and glycolysis processes of a patient with intestinal barrier injury in vitro, but also simulates interaction between food and metabolites thereof and intestinal tracts through introduction of organoids. The model can be used for exploring the metabolic process or toxic effect of food in the body of a patient suffering from intestinal barrier injury, evaluating the bioaccessibility, metabolic fate, interaction with microorganisms and influence on intestinal physiology of the food, and realizing precise risk assessment.